In the field of the development of CTGF-targeting siRNA, OliX Pharmaceuticals has established a series of candidates, such as OLX101, OLX201, OLX301, and OLX701, which were used in the treatment of hypertrophic scars, idiopathic pulmonary fibrosis, macular degeneration, and liver fibrosis [131]. This evidence concerns the gene CCN2 and idiopathic pulmonary fibrosis.